Abstract
A gas chromatographic method for measuring concentrations of a novel D1 antagonist SCH 39166 [(−)-trans-6,7,7a,8,9,13b-hexahydro-3-chloro-2-hydroxy-N-methyl-5-H-benzo[d]naphto(2,1–6)azepine] in rat brain and plasma was developed. The method was applied to descriptive pharmacokinetics of two subcutaneous doses of SCH 39166 (0.25 mg/kg and 2.5 mg/kg). For comparison, concentrations of the “prototype” D1 antagonist SCH 23390 (0.25 mg/kg, SC) [R-(+)-chloro-2,3,4,5-tetrahydro-3-methyl-5-phenyl-1-H-3-benzazepine] were also measured in plasma and brain. SCH 23390 (0.25 mg/kg, SC) had a very short elimination half-life of about 30 min in plasma, and disappeared in a slightly slower manner from striatum and cortex. SCH 39166 (0.25 and 2.5 mg/kg, SC), however, had a longer elimination half-life of about 1.5–2.5 h in plasma and brain. Interestingly, the 2.5 mg/kg dose of SCH 39166 produced only two-to five-fold increases in maximum concentrations in plasma and brain compared to the 0.25 mg/kg dose. The reason for this is not clear. The ability of these two doses of SCH 39166 to induce catalepsy in the bar test was also evaluated. It was found that SCH 39166 in these two doses, unlike SCH 23390, was not cataleptic. In conclusion, these pharmacokinetic features of SCH 39166 in the rat should be useful when designing experiments with this novel selective D1 antagonist. Furthermore, the longer elimination half-life of SCH 39166 makes it a more useful probe in pharmacodynamic comparisons of D1 receptor antagonists and classical as well as atypical neuroleptics.
Similar content being viewed by others
References
Bischoff S, Heinrich M, Sonntag GM, Krauss J (1986) The D-1 dopamine receptor antagonist SCH 23390 also interacts potently with brain serotonin (5-HT2) receptors. Eur J Pharmacol 129:367–370
Cernansky JG, Bellows EP, Barnes DE, Lombrozo L (1990) Sensitization versus tolerance to the dopamine turnover-elevating effects of haloperidol: the effect of regular/intermittent dosing. Psychopharmacology 101:519–524
Chipkin RE (1990) Dopamine D1 receptor antagonists and schizophrenia — D1 antagonist in clinical trial. TIPS 11:185
Chipkin R, Iorio LC, Coffin VL, McQuade RD, Berger JG, Barnett A (1988) Pharmacological profile of SCH 39166: a dopamine D1 selective benzonaphtaazepine with potential antipsychotic activity. J Pharmacol Exp Ther 247:1093–1102
Coffin VL, Latarnyi MB, Chipkin RE (1989) Acute extrapyramidal syndrome in cebus monkeys: development mediated by dopamine D2 but not D1 receptors. J Pharmacol Exp Ther 249:769–774
Halldin C, Farde L, Barnett A, Sedvall G (1990) Preparation of [C-11]-SCH 39166, a new selective D1 dopamine receptor ligand. J Nucl Med 31:737
Hietala J, Lappalainen J, Koulu M, Syvälahti E (1990) D1 dopamine receptor antagonists in schizophrenia — is there reduced risk for extrapyramidal side-effects? TIPS 11:406–410
Hyttel J (1983) SCH 23390 — the first selective dopamine D-1 receptor antagonist. Eur J Pharmacol 91:153–154
Iorio LC, Barnett A, Leitz FH, Houser VP, Korduba CA (1983) SCH 23390, a potential benzazepine antipsychotic with unique interactions on dopaminergic systems. J Pharmacol Exp Ther 226[2]:462–468
Kerkman DJ, Ackerman M, Artman LD, MacKenzie RG, Johnson MC, Bednarz L, Montana W, Asin KE, Stampfli H, Kebabian JW (1989) A-69024: a non-benzazepine antagonist with selectivity for the dopamine D1 receptor. Eur J Pharmacol 166:481–491
Kilts CD, Dew KL, Ely TD, Mailman R (1985) Quantification of R-(+)-7-chloro-8-hydroxy-l-phenyl-2,3,4,5-tetrahydro-1H-3-methyl-3-benzazepine in brain and blood by use of reversed-phase high-performance liquid chromatography with electrochemical detection. J Chromatogr 342:452–457
Lappalainen J, Hietala J, Syvälahti E (1989) Differential tolerance to cataleptic effect of SCH 23390 and haloperidol after repeated administration. Psychopharmacology 98:472–475
Lappalainen J, Hietala J, Koulu M, Seppälä T, Sjöholm B, Syvälahti E (1990) Chronic treatment with SCH 23390 and haloperidol: effects on dopaminergic and serotonergic mechanisms in rat brain. J Pharmacol Exp Ther 252:845–852
McQuade RD, Duffy RA, Anderson CC, Chipkin RE, Barnett A (1990) Protection of receptors from EEDQ-inactivation by SCH 39166. FASEB J 4:A601
Morelli M, DiChiara G (1985) Catalepsy induced by SCH 23390 in rats. Eur J Pharmacol 117:179–185
Nowak G, Arnt J, Hyttel J (1988) EEDQ, a tool for ex vivo measurement of occupancy of D1 and D2 dopamine receptors. Eur J Pharmacol 153:309–311
Waddington JW (1988) Therapeutic potential of selective D1 dopamine receptor agonists and antagonists in psychiatry and neurology. Gen Pharmacol 19:55–60
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Hietala, J., Seppälä, T., Lappalainen, J. et al. Quantification of SCH 39166, a novel selective D1 dopamine receptor antagonist, in rat brain and blood. Psychopharmacology 106, 455–458 (1992). https://doi.org/10.1007/BF02244814
Received:
Revised:
Issue Date:
DOI: https://doi.org/10.1007/BF02244814